PIQ-PHARMA LAUNCHES NEW MEDICATION RUPADOX®

LLC "PIQ-PHARMA" is pleased to announce the introduction of the medication Rupadox® into the civilian market. This product is available in the form of an oral solution (1 mg/ml) in a 50 ml bottle.

Rupadox® is the first and only domestic medication based on rupatadine, designed for the effective treatment of allergies in adults and children over the age of 2.

Rupadox® is a next-generation antihistamine with a dual mechanism of action: it blocks peripheral H1 histamine receptors and inhibits the activity of platelet-activating factor, providing both anti-allergic and anti-inflammatory effects.

Thus, the medication targets key pathways involved in the development of allergic reactions and can be used for both acute and chronic forms of allergic diseases, providing rapid and sustained control of allergy symptoms.

The liquid dosage form ensures faster absorption of the medication. Proven efficacy and safety, along with the ability to be used from an early age, make Rupadox® the optimal choice for the treatment of allergic rhinitis and urticaria. Rupadox® (INN: Rupatadine) is included in the Clinical Guidelines for "Allergic Rhinitis" and "Urticaria."